Stenzl - Figure 36
MSK-IMPACT Clinical Workflow for Tissue Sequencing
FIG. 36: In a recent presentation,[24] a group from Memorial Sloan Kettering Cancer Center compared the profiles of cell-free DNA extracted from plasma versus tissue and metastatic urothelial carcinoma. Data from a very small group of patients revealed that this information led to a different treatment strategy than initially planned and to a good outcome. The patients did not receive either cisplatin- or carboplatin-based chemotherapy but went on to have a checkpoint inhibitor (or in reverse order), and in other cases a treatment was stopped or continued.
References
Cheng ML, Shady M, Cipolla CK, et al. Comparison of somatic mutation profiles from cell free DNA (cfDNA) versus tissue in metastatic urothelial carcinoma (mUC). J Clin Oncol. 2017;35(suppl):Abstract 4533 http://abstracts.asco.org/199/AbstView_199_194122.html
